1. Neurodevelopmental and synaptic defects in DNAJC6 parkinsonism, amenable to gene therapy.
- Author
-
Abela, Lucia, Gianfrancesco, Lorita, Tagliatti, Erica, Rossignoli, Giada, Barwick, Katy, Zourray, Clara, Reid, Kimberley M, Budinger, Dimitri, Ng, Joanne, Counsell, John, Simpson, Arlo, Pearson, Toni S, Edvardson, Simon, Elpeleg, Orly, Brodsky, Frances M, Lignani, Gabriele, Barral, Serena, and Kurian, Manju A
- Subjects
- *
MOVEMENT disorders , *GENE therapy , *INDUCED pluripotent stem cells , *NEURAL development , *PARKINSONIAN disorders , *SYNAPTIC vesicles - Abstract
DNAJC6 encodes auxilin, a co-chaperone protein involved in clathrin-mediated endocytosis (CME) at the presynaptic terminal. Biallelic mutations in DNAJC6 cause a complex, early-onset neurodegenerative disorder characterized by rapidly progressive parkinsonism-dystonia in childhood. The disease is commonly associated with additional neurodevelopmental, neurological and neuropsychiatric features. Currently, there are no disease-modifying treatments for this condition, resulting in significant morbidity and risk of premature mortality. To investigate the underlying disease mechanisms in childhood-onset DNAJC6 parkinsonism, we generated induced pluripotent stem cells (iPSC) from three patients harbouring pathogenic loss-of-function DNAJC6 mutations and subsequently developed a midbrain dopaminergic neuronal model of disease. When compared to age-matched and CRISPR-corrected isogenic controls, the neuronal cell model revealed disease-specific auxilin deficiency as well as disturbance of synaptic vesicle recycling and homeostasis. We also observed neurodevelopmental dysregulation affecting ventral midbrain patterning and neuronal maturation. To explore the feasibility of a viral vector-mediated gene therapy approach, iPSC-derived neuronal cultures were treated with lentiviral DNAJC6 gene transfer, which restored auxilin expression and rescued CME. Our patient-derived neuronal model provides deeper insights into the molecular mechanisms of auxilin deficiency as well as a robust platform for the development of targeted precision therapy approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF